All In Biotech

NDA 020500 · Glaxosmithkline LLC

Mepron

Atovaquone · Oral · Antimalarial; Antiprotozoal

Priority review

Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Feb 8, 1995

Approved uses

2

Original approval plus efficacy supplements

Registered trials

57

5 Phase 3, 2 recruiting

FAERS reports

8,218

7,018 serious, 1,382 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 20, 2026.

MEPRON oral suspension is a quinone antimicrobial drug indicated for: • Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). ( 1.1 ) • Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. ( 1.2 ) Limitations of Use ( 1.3 ) : • Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2 ] >45 mm Hg) with MEPRON has not been studied. • The efficacy of MEPRON in subjects who are failing therapy with TMP-SMX has also not been studied. 1.1 Prevention of Pneumocystis jirovecii Pneumonia MEPRON oral suspension is indicated for the prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). 1.2 Treatment of Mild-to-Moderate Pneumocystis jirovecii Pneumonia MEPRON oral suspension is indicated for the acute oral treatment of mild-to-moderate PCP in adults and adolescents (aged 13 years and older) who cannot tolerate TMP-SMX. 1.3 Limitations of Use Clinical experience with MEPRON for the treatment of PCP has been limited to subjects with mild-to-moderate PCP (alveolar-arterial oxygen diffusion gradient [(A-a)DO 2 ] ≤45 mm Hg). Treatment of more severe episodes of PCP with MEPRON has not been studied. The efficacy of MEPRON in subjects who are failing therapy with TMP-SMX has also not been studied.

Mechanism: Atovaquone is a quinone antimicrobial drug [see Microbiology ( 12.4 )] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 5, 1999 Supplement 5 · Efficacy ReviewLabelLetter
  • Feb 8, 1995 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • MEPRON · ATOVAQUONE 750MG/5ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Atovaquone" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use833
  • pyrexia453
  • diarrhoea435
  • drug ineffective426
  • nausea406
  • pneumonia393
  • death323
  • fatigue313
  • dyspnoea298
  • acute kidney injury292
  • neutropenia279
  • condition aggravated278

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200442
200552
200652
200760
200882
2009105
201090
201189
2012126
2013134
2014170
2015209
2016240
2017272
2018373
2019403
2020570
2021668
2022836
2023956
2024993
2025986
2026710

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mepron (Atovaquone)

2024 spending

$251K

Beneficiaries

28

144 claims

Per beneficiary

$8,977

$6.14 per unit

View as table
YearSpending
2020$423,828
2021$435,587
2022$316,549
2023$322,206
2024$251,362

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 135 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.